摘要
目的研究MIB1（Ki-67的单克隆抗体）与DNA拓扑异构酶Ⅱα（TopoⅡα）在弥漫大B细胞淋巴瘤（DLBCL）的表达情况，探讨其与临床分期及生存时间的关系。方法收集山西省肿瘤医院病理科1996年至2001年确诊的DLBCL住院病例66例，按WHO（2001）淋巴造血系统肿瘤分类标准确定诊断，应用ABC法常规标记CD3、CDmCD79α、Pax5，应用免疫双标记ABC—DAB／SABAP-vector red显示CD20阳性细胞表达MIB1，ABC-DAB／免疫胶体金显示CD20阳性细胞表达TopoⅡα，不进行苏木精复染。结果MIBl与TopoⅡα标记指数与临床分期有关，在低级别临床分期（I、II期）的表达指数低于高级别（Ⅲ、IV期）（P〈0．05）。MIBl与TopoⅡα的表达与生存时间呈线性相关（r=-0．487，r=0．251，P〈0．05）。结论MIB1与TopoⅡα可以作为DLBCL独立的预后指标。
Objective To investigate the expression of MIB1 and Topo Ⅱα, and their relation to the clinical grades and biological behavior in diffuse large-B cell lymphoma （DLBCL）. Methods 66 cases of DLBCL were selected from the Pathological Department of Shanxi Tumor Hospital from 1996 to 2001. An ABC method was used to detect the expression of CD3, CD20, CD79α, Pax5, and a double immunostaining technique ABC-DAB/SABAP-vector red and ABC-DAB/ immunogolden was used to detect the expression of MIB1 and Topo Ⅱα. Results Expression of MIB1 and Topo Ⅱα were increased along with the clinical stage of the DLBCL. There was a significant difference between caller stage （ I , Ⅱ ）and later stage （Ⅲ, Ⅳ ） in DLBCL （P 〈0.05）. The expression of MIBI and Topo Ⅱα were also significantly related to the survival rate（r =-0.487, 0.251 respectively, P 〈0.05）. Conclusion Expression of MIB1 and Topo Ⅱα may serve as two independent prognostic predictors in DLBCL.
出处
《白血病．淋巴瘤》
CAS
2008年第5期367-368,371,共3页
Journal of Leukemia & Lymphoma
